Biological
Therapeutic Dendritic Cells/Cytokine-induced Killer Cells clinical trials
- studies test it
- 14
- open now
- 2
- in phase 3
- 1
- first study started
- 2009
Keep track of what changes. Save the Therapeutic Dendritic Cells/Cytokine-induced Killer Cells studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 5 |
| 2017 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 13
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 11
Shenzhen Hornetcorn Bio-technology Company, LTD (3) · Guangxi Medical University (3) · Fuda Cancer Hospital, Guangzhou (2) · Capital Medical University (1) · The First People's Hospital of Changzhou (1) · JIANG LONGWEI (1) · National Taiwan University Hospital (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1)
Studies
Open first, then newest update. How each study uses Therapeutic Dendritic Cells/Cytokine-induced Killer Cells is read from its arms, and is right about nine times in ten.
Testing it · 14
- Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.RecruitingEarly Phase 1JIANG LONGWEINCT07343791Written as DC-CIK combined with regorafenib ,Iparomlimab and Tuvonralimab Injection
- DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in TreatingNot yet recruitingPhase 2The First People's Hospital of ChangzhouNCT02487550Written as DC-CIK
- Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver CancersStatus unknownPhase 1/2National Taiwan University HospitalNCT05622825Written as DC-CIK
- Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)CompletedPhase 1/2Fuda Cancer Hospital, GuangzhouNCT02425748Written as DC-CIK
- Study of S-1 Plus DC-CIK for Patients With Advanced Gastric CancerCompletedPhase 1/2Capital Medical UniversityNCT01783951Written as DC-CIK
- Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)CompletedPhase 1/2Fuda Cancer Hospital, GuangzhouNCT02418481Written as DC-CIK
- Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal CancerStatus unknownPhase 2Shenzhen Hornetcorn Bio-technology Company, LTDNCT02644863Written as DC-CIK
- DC-CIK Combined With TACE in the Treatment of Hepatocellular CarcinomaStatus unknownPhase 2Shenzhen Hornetcorn Bio-technology Company, LTDNCT02487017Written as DC-CIK
- Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal CancerStatus unknownPhase 2Shenzhen Hornetcorn Bio-technology Company, LTDNCT02202928Written as DC-CIK
- DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal CancerStatus unknownPhase 2/3Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT02415699Written as DC-CIK
- Study of DC-CIK to Treat Colorectal CancerStatus unknownPhase 2Guangxi Medical UniversityNCT01839539Written as dendritic and cytokine-induced killer cells
- A Study of DC-CIK to Treat Hepatocellular CarcinomaStatus unknownPhase 2Guangxi Medical UniversityNCT01821482Written as Dendritic and Cytokine-induced Killer Cells
- Study of DC-CIK to Treat NPCStatus unknownPhase 2Guangxi Medical UniversityNCT01821495Written as DC-CIK
- DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell CarcinomaStatus unknownPhase 1/2Fuzhou General HospitalNCT00862303Written as DC-CIK